After a sublethal exposure to lipopolysaccharide (LPS) 
Endotoxin, the lipopolysaccharide (LPS) derived from cell walls of gram-negative bacteria, has been shown to induce many of the harmful manifestations seen in patients with gram-negative sepsis. Among these are pyrogenic activity, hypoglycemia, and changes in blood clotting and in blood pressure which can result in shock or death (reviewed in reference 1). However, some of the effects of endotoxin are beneficial, i.e., immunogenicity, protection against lethal irradiation, immune adjuvant effects, and enhancement of nonspecific resistance to infection or to toxic doses of endotoxin (reviewed in reference 2). Because humans are very sensitive to the toxic effects of endotoxin, therapeutic approaches which involve the use of endotoxin to induce beneficial effects have been limited. The toxic activity of the endotoxin molecule has been shown to reside in the lipid A portion of the LPS molecule which consists of a phosphorylated glucosamine disaccharide unit substituted with esterand amide-linked long-chain fatty acids. Recent advances in chemical modification techniques and chromatography have allowed the isolation, purification, and characterization of nontoxic and toxic lipid A analogs from polysaccharidedeficient, heptoseless Re mutants of Salmonella typhimurium or Salmonella minnesota (9, 11, 12, 16, 17) . A monophosphoryl lipid A (MPL) derivative has recently been described (17) , purified (9) , and demonstrated to be at least 1,000 times less toxic or pyrogenic for rabbits than either the parent endotoxin or diphosphoryl lipid A (15, 17) .
In this study, we focused on one of the beneficial effects of endotoxin,-the induction of a state of hyporesponsiveness to LPS, which is referred to as endotoxin tolerance. Briefly stated, endotoxin tolerance can be induced after an initial, sublethal exposure to LPS, which renders experimental animals or people refractory to subsequent LPS challenge.
* Corresponding author.
Endotoxin tolerance has been divided temporally into two phases. Early-phase endotoxin tolerance occurs within the first few days after exposure to LPS, is transient, and is not 0-antigen specific. Late-phase tolerance is related to the production of anti-O-specific antibodies, occurs several weeks after the initial exposure to LPS, and persists for several weeks (3) . Recent work by Williams et al. (19) and Madonna and Vogel (6) has provided insights into the cellular mechanisms which underlie the induction of earlyphase endotoxin tolerance. Williams et al. demonstrated the involvement of lymphoid cell types derived principally from the peritoneal cavity and spleen for the abrogation of early endotoxin tolerance. Madonna and Vogel found that the induction and maintenance of early endotoxin tolerance is associated with a marked increase in bone marrow-derived macrophage progenitor cells (macrophage-CFU [M-CFU]). This suggested that early endotoxin tolerance might be related to an accumulation of immature monocytic precursors in the bone marrow which could, in turn, result in reduced availability of mature (and more LPS-responsive) monocytic cells in the periphery.
The primary goal of this work was to assess the efficacy of the nontoxic, MPL Reagents. Detoxified endotoxin (MPL, lot 375) from an S. typhimurium Re mutant was obtained from Ribi ImmunoChem Research, Inc., Hamilton, Mont. The MPL, 1 mg per vial, was solubilized by the addition of 0.5 ml of sterile distilled water, followed by swirling the suspension in a 65 to 70°C water bath for 10 to 20 s and by sonication for 10 to 20 s. After three to four cycles of heating and sonication, the solution clarified to slight opalescence. To this solution was added 0.5 ml of 3.6% NaCl to give a final stock solution of MPL (1 mg/ml) which was subjected to one additional cycle of heating and sonication.
Protein-free, phenol-water-extracted E. coli K235 LPS was prepared by the method of McIntire et al. (5) . This LPS preparation was sonicated in pyrogen-free saline at a final concentration of 1 mg/ml.
Measurement of CSF activity in serum. Serum was tested for CSF activity in a bone marrow colony assay in semisolid agar as described previously (19) . Briefly, serum was obtained from pooled blood collected from the orbital plexus of mice 6 h after the injection of saline, LPS, or MPL. Various dilutions of the serum were then made in six-well tissue culture plates (Costar, Cambridge, Mass.). Bone marrow cells were obtained from the femurs and tibias of C3H/HeJ mice and were further processed by density gradient centrifugation in lymphocyte separation medium (Litton Bionetics, Charleston, S.C.) to enrich for mononuclear cells. The cells were then collected from the gradient interface and were enumerated (model ZM; Coulter Electronics Ltd., England). The bone marrow cells were then diluted to a final concentration of 105 cells per ml in RPMI 1640 medium supplemented with antibiotics, HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer, glutamine, 15% fetal calf serum, and 0.3% molten agar. Then, 1 ml of the cell suspension in agar was added to each of the wells which contained 0.2 ml of the serum dilution, swirled to allow mixing, and allowed to solidify. Cultures were then incubated at 37°C (5% C02) for 7 days at which time bone marrow colonies (>50 cells per colony) were enumerated with an inverted microscope. Cytochemical staining of colonies revealed that >90% of the colonies were of macrophage lineage. Serum CSF activity is expressed as CFU per milliliter of serum.
Measurement of IFN activity in serum. The level of IFN in serum samples collected 2 h after intravenous (i.v.) administration of saline, LPS, or MPL was measured by antiviral activity (13) which tests the ability of the serum to protect murine L929 fibroblasts from infection with vesicular stomatitis virus (Indiana strain). The details of this assay are described elsewhere (18 (10) .
Determination of the number of macrophage progenitor cells M-CFU in the bone marrow. The number of macrophage progenitor cells per femur was determined as described elsewhere (6) . Briefly, groups of five mice were injected i.p. with saline, E. coli LPS, or various doses of MPL as indicated. After 3 days, the mice from each group were killed, and five femurs per group (one femur per mouse) were homogenized to obtain a bone marrow cell suspension. A portion of the cell suspension was used to obtain a nucleated cell count and cell sizing profile with a Coulter Counter model ZM and Coulter Channelyzer C1000.
The number of macrophage progenitor cells (M-CFU), adjusted for the total nucleated cell count from each cell suspension, was then determined by using a double-layer, semisolid agar colony assay (4) . Although the single-layer colony assay is adequate for the assessment of CSF levels in serum (7-day incubation period), the double-layer assay is preferred for enumeration of progenitor cells because it is nutritionally enriched to accommodate the longer (10 day) incubation period and provides some protection against desiccation. Approximately 7,000 U of partially purified, macrophage-specific CSF (CSF-1) was contained in the bottom layer. The upper layer contained 5 x 104 bone marrow cells from each group. Duplicate cultures were incubated for 10 days at 37°C (5% C02), and colonies (>50 cells) were counted.
RESULTS
Induction of serum CSF by MPL. Previous studies have revealed that injection of endotoxin into mice was followed by a rapid rise of serum CSF which reached a maximum level at approximately 6 h postinjection (7) . To test whether the nontoxic lipid A derivative, MPL, was also able to induce this manifestation of endotoxin responsiveness, groups of five mice were injected i.v. with various doses of MPL. At 6 h after injection, the mice were bled, and the serum was subsequently tested for the presence of CSF. Serum CSF was induced over a wide dose range (1.0 to 100 ,ug per mouse) and was induced optimally at 50 ,ug of MPL per mouse (Fig. 1A) . Additionally, MPL induced a similar (although somewhat reduced) dose-dependent response in mice injected i.p. (data not shown).
Induction of early endotoxin tolerance by MPL to challenge with intact E. coli K235 LPS. In two previous reports in which CSF was used as an indicator of in vivo LPS responsiveness, it was found that early endotoxin tolerance was optimal 3 to 4 days after initial exposure to either a homologous or heterologous preparation of LPS (6, 19) . To test whether an initial exposure to MPL would also render animals refractory to LPS, we injected groups of mice with various concentrations of MPL, and 3 days later we challenged these same mice with E. coli LPS (25 ,ug per mouse). At 6 h after challenge, blood was collected, and the serum was assayed for CSF. The results show that increasing the dose of MPL given on day 0 reduced significantly the serum CSF response induced upon challenge with 25 pug of E. coli LPS on day 3 (Fig. 1B) was equivalent to that seen when E. coli LPS was used as the by MPL for IFN was less striking than the tolerance induced tolerogen (Fig. 1B) .
by the intact LPS for IFN or the MPL-induced tolerance for Another indication of in vivo LPS responsiveness is the CSF (Fig. 1B) . induction of serum IFN which usually peaks 2 to 3 h after The effect of initial MPL exposure on LPS-induced LD50 i.v. administration of intact LPS or lipid A (20). The level of was also determined. It was found that prior exposure of serum IFN induced by MPL was comparable to that stimumice to an initial dose of MPL (100 ,ug per mouse) signifilated by E. coli LPS (Fig. 2) ; however, the tolerance induced cantly increased the LD50 to E. coli LPS approximately fivefold (1, 156 jig of LPS in mice with MPL-induced tolerance versus 258 ,ug of LPS in control, saline-treated mice). This increase was found to be comparable to that induced by E. coli LPS (972 ,ug). Additionally, it was found that prior exposure of MPL on day 0 essentially eliminated LPSinduced symptoms of endotoxicity after LPS challenge on day 3 (i.e., ruffled fur, conjunctival discharge, and diarrhea).
MPL-induced changes in the number of bone marrowderived macrophage progenitor cells. Previous studies have shown that injection of E. coli LPS on day 0 greatly increased the number of CSF-responsive macrophage progenitor cells (M-CFU) by day 3 after injection (the optimal day for early endotoxin tolerance). To test the efficacy of MPL to increase bone marrow M-CFU, groups of five mice were injected with saline, E. coli LPS (25 jig per mouse), or various concentrations of MPL, and on day 3 after injection, bone marrow cells from the femurs of each group were enumerated and cultured in an excess of CSF-1. This factor has been shown to be specific for cells of macrophage lineage and to give rise exclusively to macrophage colonies in culture (14) . The results show that MPL increased the number of M-CFU in the bone marrow in a dose-dependent fashion (Fig. 3 ). When mice were given 100 jig of MPL per mouse, the level of M-CFU per femur was equal to that induced by 25 ,ug of E. coli LPS.
These findings were further supported by changes in bone marrow cell sizing profiles obtained with a Coulter Channelyzer. Previous work showed that injection of E. coli LPS on day 0 resulted in an increase in size and cell number of the Coulter Channelyzer profile peak 2 which was found to contain all of the macrophage progenitor activity (6) . Bone marrow cell suspensions from groups of five mice injected 3 days earlier with saline, E. coli LPS, or MPL were compared by using a Coulter Channelyzer. As can be seen in Fig. 4 , like LPS, the injection of MPL induced a marked reduction in the relative number of bone marrow cells in peak 1 (20% of total) and a compensatory increase in the number of cells within peak 2 (80%). This was accompanied by an increase in cell size in peak 2 
DISCUSSION
Early-phase endotoxin tolerance occurs within the first few days after LPS exposure, fades within a week, and is inducible with serologically unrelated species of LPS (3). By following the early endotoxin tolerance protocol set forth by Williams et al. (19) , we established an early tolerance system by the injection of mice with 25 ,ug of E. coli K235 LPS (6) . By using CSF as an initial indicator of in vivo LPS responsiveness, it was found that maximal hyporesponsiveness to a challenge injection occurred 3 to 4 days after the initial injection. It was shown in that study that the acquisition and maintenance of the tolerant state coincided temporally with an increase in the number of macrophage progenitor cells in the bone marrow. Further, density gradient separation and cell sizing profiles confirmed that the bone marrow cell populations of mice with MPL-induced tolerance exhibited an increase in cell size and in the number of macrophage precursors.
By using a modification of this early endotoxin tolerance system, we replaced the toxic, wild-type E. coli LPS used on day 0 in our previous study with a nontoxic, MPL derivative to assess its ability to induce early tolerance. Unlike initial An intriguing aspect of this study is that tolerance, as assessed by IFN production, was less affected by MPL than other manifestations of LPS responsiveness are. One possible implication is that IFN may be less involved in the induction of the toxic effects of LPS than other serum factors, such as serum CSF. In this regard, previous work by Moore et al. (8) supports a role for CSF as an immunoregulatory agent capable of rendering macrophages more sensitive to LPS in vitro as assessed by increased production of IFN and interleukin-1.
The major obstacle which has limited the clinical application of endotoxin for its beneficial effects has been its toxic side effects. Chemical modification of the endotoxin molecule has resulted in a nontoxic, MPL which, because of its greatly reduced capacity to cause endotoxicity, holds great potential for clinical utilization.
